AstraZeneca (NYSE:AZN) Stock Rating Upgraded by StockNews.com

Posted by on Jan 21st, 2023

AstraZeneca (NYSE:AZN – Get Rating) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday.

AstraZeneca Stock Performance

NYSE AZN opened at $69.15 on Thursday. AstraZeneca has a 52 week low of $52.65 and a 52 week high of $72.12.

About AstraZeneca

(Get Rating)

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Read More

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.